Compare UPST & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UPST | VCEL |
|---|---|---|
| Founded | 2012 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2020 | 1996 |
| Metric | UPST | VCEL |
|---|---|---|
| Price | $17.01 | $58.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 8 |
| Target Price | $30.50 | ★ $65.43 |
| AVG Volume (30 Days) | ★ 4.6M | 819.8K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.25 | 60.00 |
| EPS | ★ 0.44 | 0.19 |
| Revenue | ★ $1,043,857,000.00 | $276,259,000.00 |
| Revenue This Year | $25.80 | $24.98 |
| Revenue Next Year | $28.65 | $15.37 |
| P/E Ratio | ★ $41.25 | $308.26 |
| Revenue Growth | ★ 63.99 | 16.45 |
| 52 Week Low | $18.04 | $28.95 |
| 52 Week High | $52.10 | $59.75 |
| Indicator | UPST | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 29.31 | 72.49 |
| Support Level | N/A | $31.94 |
| Resistance Level | $24.92 | $59.75 |
| Average True Range (ATR) | 1.38 | 2.53 |
| MACD | -0.39 | 0.60 |
| Stochastic Oscillator | 3.65 | 90.60 |
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The company support development of different lending product offerings, which are grouped into three operating segments - Personal Lending (unsecured personal loans and small dollar loans), Auto Lending (auto refinance, auto retail loans, and auto secured personal loans), and Other (HELOCs and other).
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.